Ambry Genetics and SoftGenetics Form Alliance for Extended Bioinformatics Support for Sequencing Projects
News Dec 04, 2009
Ambry Genetics and SoftGenetics have announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics’ NextGENe software for next-generation sequencing projects performed at Ambry.
Anja Kammesheidt PhD, Ambry’s CSO said, “Our team at Ambry has been providing genomics solutions on Illumina’s® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics’ software tools, as well as their approach to take care of the clients’ needs which is very much in line with Ambry’s philosophy. We are looking forward to working together to provide tailored services to our clients.”
Jonathan Liu PhD, SoftGenetics VP Research and Development echoed Dr. Kammesheidt’s thoughts and added that “the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software.”
“This highly unique alliance” , continued John Fosnacht, SoftGenetics VP Sales and Marketing, “provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone.”
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.
Bubble formation is typically a much more random process than liquid droplet formation, yet the generation of uniform drops and bubbles is very desirable in microfluidics. Researchers have now shown that under certain conditions, bubbles can also be coaxed to form spheres as perfectly matched as droplets.READ MORE